A landmark 2026 brain imaging study identified three distinct ADHD biotypes. Here’s why that matters if you’re an adult in Saskatchewan who’s been told “just try a different dose.”
Most adults with ADHD have heard some version of the same thing: the medication should help. And when it doesn’t — or when it helps with focus but leaves the emotional storms untouched — the assumption is that something else must be going on. Maybe it’s depression. Maybe it’s bipolar disorder. Maybe you’re just not trying hard enough.
Here’s what that line of thinking misses: ADHD isn’t one condition with one brain pattern. A major study published in JAMA Psychiatry in February 2026 used structural MRI data from over 1,800 participants to identify three neurobiologically distinct ADHD biotypes — each with different brain circuit alterations, different symptom profiles, and potentially different treatment needs. The study was replicated in an independent cohort of 554 additional children with ADHD, and the three biotypes held up.
This isn’t a personality quiz. It’s the first time researchers have used brain-first, data-driven methods — no symptom checklists, no clinical impressions feeding the algorithm — and arrived at groupings that map cleanly onto recognizable clinical patterns.
If you’ve been bouncing between providers in Saskatoon, Regina, Prince Albert, or La Ronge wondering why nothing quite clicks, this research might offer the first real explanation.
The short version:
- ADHD appears to have three brain-based subtypes, not just the behavioural categories in the DSM-5
- One of those subtypes — the one dominated by emotional dysregulation — is the most severe, the most persistent, and the most likely to be mistaken for a mood disorder
- Your treatment approach should account for which pattern fits you, not just whether you meet a symptom threshold
- This is still early research — no one is offering “biotype testing” in clinic yet — but the implications for treatment matching are already clinically useful
What most people miss: The emotional dysregulation subtype (Biotype 1) had the most widespread brain differences of all three groups, yet it’s the one most likely to be dismissed as “just anxiety” or “probably bipolar.” If your ADHD treatment has focused exclusively on attention and you’ve been told your emotional reactivity is a separate problem, the science is starting to suggest otherwise.
Three Biotypes, Three Different Brains
The study, led by Dr. Nanfang Pan and colleagues at West China Hospital of Sichuan University and Monash University, used a technique called morphometric similarity network analysis. In plain language: they mapped how different brain regions structurally resemble each other, then looked for patterns of deviation from what’s typical for a given age and sex — similar to how a pediatric growth chart flags unusual development, but for brain architecture.
They didn’t tell the algorithm what ADHD “should” look like. They fed it brain data from 446 children with ADHD and 708 typically-developing children across multiple research sites, and the clustering fell into three groups on its own.
Biotype 1: The Emotional Dysregulation Profile
This is the one that matters most for adults who’ve felt failed by the system.
Biotype 1 showed the most widespread brain differences of any group, concentrated in connections between the medial prefrontal cortex and the pallidum — a deep brain structure involved in motivation and emotional regulation. Children in this group had the highest levels of both inattention and hyperactivity/impulsivity, and over a four-year follow-up, they showed the most persistent difficulties with emotional self-regulation. Their brain deviation patterns corresponded with serotonin, dopamine, and acetylcholine system distributions — all neurotransmitter systems previously linked to ADHD.
Here’s the clinical kicker: this group also had higher rates of mood disorder comorbidity during follow-up. Not because they had a separate mood disorder, but because the emotional dysregulation baked into their ADHD biotype looks, on the surface, a lot like one.
If you’re an adult who was first diagnosed with depression or bipolar disorder, tried mood stabilizers that didn’t help, and only later received an ADHD diagnosis — Biotype 1 is likely what was going on all along. Research consistently shows that 34–70% of adults with ADHD experience significant emotional dysregulation, and those individuals are routinely misdiagnosed with mood disorders before ADHD is identified.
The European Psychiatric Association already lists emotional dysregulation as one of six fundamental features of adult ADHD. The DSM-5, which guides most North American diagnosis, still treats it as an “associated feature” — a footnote, essentially. That gap between European and North American diagnostic frameworks is one reason so many Saskatchewan adults fall through the cracks.
Biotype 2: The Hyperactive-Impulsive Profile
Biotype 2 showed brain alterations concentrated in the anterior cingulate cortex and pallidum — circuits that handle action control and response selection. This maps onto a predominantly hyperactive/impulsive presentation: difficulty waiting, acting before thinking, restlessness that goes beyond physical fidgeting into a constant internal pressure to do something.
The neurochemical signatures here were associated with glutamate and cannabinoid receptor distributions — a different chemical landscape entirely from Biotype 1.
In adults, this profile is actually the one most likely to show improvement over time. The hyperactive-impulsive presentation tends to have trajectories of natural improvement as the brain matures, which is part of why some adults feel like they’ve “grown out of” their ADHD. They haven’t — the impulsivity has often just shifted from visible behaviour (blurting things out, physical restlessness) to internal experience (impatience, difficulty with delayed gratification, impulsive spending or decision-making).
For treatment, this is the biotype that tends to respond most straightforwardly to stimulant medication — the classic “I took Vyvanse and my brain got quiet for the first time” experience.
Biotype 3: The Inattentive Profile
Biotype 3 showed more focal differences in the superior frontal gyrus, a region involved in sustained attention. Brain patterns here linked to a specific serotonin receptor subtype.
This is the “quiet ADHD” — the daydreamer, the person who reads the same paragraph six times, the employee who has fifteen browser tabs open and can’t remember why any of them are there. It’s also the presentation most underdiagnosed in women, because it doesn’t disrupt classrooms or workplaces in visible ways.
Adults with an inattentive-dominant profile often don’t get diagnosed until their thirties or forties, typically when life complexity outpaces their compensatory strategies. The Saskatchewan adult who managed fine on the farm or in a structured trade suddenly struggles when they take on supervisory responsibilities, or when a life transition (new baby, aging parent, career change) exceeds their organizational bandwidth.
Treatment for this biotype often benefits from a combined approach: medication to sharpen focus, plus structured skills training for time management, task initiation, and what I’d call “externalization strategies” — making the invisible executive function work visible and concrete.
Why This Matters for Treatment Matching
The standard approach to ADHD treatment in Canada follows a fairly predictable path: you get diagnosed, you try a stimulant, your doctor adjusts the dose, and if that doesn’t work, you try a different stimulant or a non-stimulant like atomoxetine. Maybe someone mentions CBT. Repeat until something sticks or you give up.
The biotype research suggests this approach is incomplete — not wrong, but incomplete. If your core difficulty is emotional regulation (Biotype 1), a stimulant that sharpens your focus while leaving your emotional reactivity untouched is going to feel like a partial fix. And that’s exactly what the evidence shows: stimulants improve attention and reduce hyperactivity reliably, but their effects on emotional dysregulation are more variable. Some studies find that amphetamine preparations can actually increase irritability and mood lability in certain individuals.
Here’s how biotype mapping changes the treatment conversation:
If emotional dysregulation is your dominant struggle (Biotype 1 pattern): You likely need more than just stimulant medication. Emotional regulation skills training — structured, evidence-based work on identifying emotional triggers, building distress tolerance, and developing flexible response patterns — should be a core part of your plan, not an afterthought. Non-stimulant medications like atomoxetine, which have shown parallel improvement in emotional regulation and core ADHD symptoms, may deserve earlier consideration. If you’ve been prescribed mood stabilizers for what was assumed to be bipolar disorder and they haven’t helped, it’s worth revisiting the primary diagnosis.
If hyperactivity-impulsivity is your main challenge (Biotype 2 pattern): Stimulant medication is your most evidence-supported starting point, and it’s likely to produce the most noticeable improvements. The work beyond medication is about building systems for impulse management in the specific contexts where impulsivity costs you — finances, relationships, career decisions. Structured pauses before action (“sleep on it” rules for purchases over a certain amount, for example) are deceptively simple and genuinely effective.
If inattention is your primary experience (Biotype 3 pattern): Medication helps, but the gap between “medicated focus” and “functional life” often requires deliberate skill-building around external organization systems, task decomposition (breaking projects into concrete next steps), and environmental design. The person who focuses fine on medication but still can’t start tasks, prioritize, or manage their calendar is experiencing an executive function challenge that medication alone won’t fully resolve.
The Saskatchewan Context
Adult ADHD services in Saskatchewan are limited, and the wait for psychiatric assessment through the public system can stretch past twelve months in many regions. If you’re in a rural or northern community, access is even more constrained. Telehealth has improved this — services like ours at saskadhd.com are specifically built to reach adults across the province — but the systemic bottleneck remains.
What makes the biotype research particularly relevant here is that Saskatchewan’s diagnostic landscape tends to follow a generalist model. Your family doctor can diagnose and prescribe for ADHD, which is genuinely helpful for access. But a fifteen-minute appointment rarely allows for the kind of nuanced assessment that distinguishes between Biotype 1 emotional dysregulation and a co-occurring mood disorder. The result: Saskatchewan adults with the emotional dysregulation profile are disproportionately likely to be on an SSRI or mood stabilizer that isn’t addressing the core problem.
If any of this resonates — if you’ve been treated for depression or anxiety or bipolar disorder and the treatment never quite fit, or if your ADHD medication handles focus but not the emotional rollercoaster — the answer probably isn’t another dose adjustment. It might be a fundamentally different treatment approach, one that matches the specific way your brain is wired.
What This Research Can’t Do Yet
Transparency matters, so here’s what this study does not mean:
You can’t walk into a clinic and get a brain scan that sorts you into Biotype 1, 2, or 3. The MRI-based clustering used in this study is a research tool, not a clinical one. The imaging protocols, normative modeling, and clustering algorithms require specialized infrastructure that doesn’t exist in clinical settings yet.
The study was conducted in children. While the brain regions and circuits identified have well-established roles in adult ADHD as well, direct validation of these biotypes in adult populations hasn’t been published yet. Longitudinal research following these children into adulthood will be critical.
The neurochemical associations are spatial and exploratory — they show that certain biotype brain patterns overlap with the distribution of specific neurotransmitter receptors, but they don’t directly prove that those neurotransmitter systems are altered in each biotype. The treatment implications are informed inferences, not direct prescriptions from the study.
Comorbidity exclusion criteria in the study were strict, meaning the real-world ADHD population — where anxiety, depression, and other conditions commonly co-occur — may not be perfectly represented.
All data came from research sites in the United States and China. Whether these biotypes hold across other populations, including Canadian Indigenous communities and Northern populations with distinct genetic ancestry, remains an open question.
Where This Is Heading
The long-term goal of this line of research is precision psychiatry for ADHD — matching treatment to neurobiology rather than to a symptom checklist. That’s still aspirational, but this study takes it from “interesting idea” to “here’s the framework.”
In the nearer term, what matters for you as an adult seeking treatment in Saskatchewan is this: the clinical impressions that experienced ADHD clinicians have relied on for years — that emotional dysregulation is a core feature of ADHD, not a separate diagnosis; that different people with ADHD need fundamentally different treatment approaches; that symptom severity alone doesn’t capture what’s happening — now have biological validation.
That’s not nothing. That’s the scientific foundation for demanding better treatment matching.
Deciding Your Next Step
If you’ve never been assessed for ADHD and what you’ve read here resonates — particularly the emotional dysregulation profile — start with a structured screening. The WHO Adult ADHD Self-Report Scale (ASRS) is a free, validated tool that gives you something concrete to bring to your doctor.
If you have an ADHD diagnosis but treatment feels incomplete, consider whether your current plan addresses the full picture. Medication without skills training, or attention-focused treatment without emotional regulation work, may leave the most impairing symptoms untouched.
If you’ve been diagnosed with a mood disorder but the treatment hasn’t worked, it’s worth asking your provider about the possibility that ADHD — particularly the emotional dysregulation presentation — is the primary condition.
At saskadhd.com, we work with adults across Saskatchewan who are navigating exactly these questions. Our assessments are designed to capture the full clinical picture, not just whether you meet a symptom count. And our treatment approach builds from what the evidence actually says works — including emotional regulation as a central pillar, not a footnote.
Sources and Methodology Notes
Primary source: Pan N, Long Y, Qin K, et al. Mapping ADHD Heterogeneity and Biotypes by Topological Deviations in Morphometric Similarity Networks. JAMA Psychiatry. Published online February 25, 2026. doi:10.1001/jamapsychiatry.2026.0001
- Study design: Case-control, multisite, cross-sectional with longitudinal follow-up subset
- Discovery sample: 446 children with ADHD, 708 typically-developing controls
- Validation sample: 554 children with ADHD from the independent Healthy Brain Network dataset
- Method: Normative modeling of morphometric similarity networks with data-driven clustering
- Key limitation: Pediatric sample; strict comorbidity exclusions; US and China sites only
Emotional dysregulation prevalence in adult ADHD: Estimates range from 34–70% across multiple studies (Shaw et al., American Journal of Psychiatry, 2014; Beheshti et al., BMC Psychiatry, 2020; Bodalski et al., Journal of Attention Disorders, 2023). The European Psychiatric Association’s 2019 consensus statement lists emotional dysregulation as a core feature of adult ADHD (Kooij et al., European Psychiatry, 2019).
ADHD and mood disorder misdiagnosis: Adults with ADHD are commonly misdiagnosed with mood disorders, particularly when emotional dysregulation is the dominant presentation (Schiweck et al., 2021; Barkley, 2020). Women with ADHD are disproportionately misdiagnosed with bipolar disorder or borderline personality disorder (Quinn & Madhoo, 2014).
Stimulant effects on emotional regulation: Two randomized controlled trials of amphetamine preparations found no beneficial medication impact on a broad range of emotional problems, with some evidence that amphetamine preparations may increase irritability (reviewed in Faraone et al., PMC, 2014). Atomoxetine has shown parallel improvement in emotional regulation and core ADHD symptoms in adults (same review).
Methodology note: Treatment matching recommendations in this article are informed clinical inferences based on the biotype research combined with existing evidence on ADHD treatment response. They do not represent direct treatment prescriptions from the Pan et al. study. The biotype framework is not yet available as a clinical diagnostic tool.
